Journal
ONCOGENE
Volume 29, Issue 9, Pages 1249-1259Publisher
SPRINGERNATURE
DOI: 10.1038/onc.2009.512
Keywords
myc; mycn; neuroblastoma; N-myc; mTor; PI3K
Funding
- NIH [CA133091, NS055750, CA102321, CA097257, CA128583]
- Burroughs Wellcome Fund
- American Brain Tumor Association
- Brain Tumor Society
- Accelerate Brain Cancer Cure
- Alex's Lemonade Stand Foundation
- Children's National Brain Tumor Foundation
- Wallace H. Coulter Foundation
- Katie Dougherty Foundation
- Pediatric Brain Tumor Foundation
- Samuel G Waxman Foundation
- V Foundation
Ask authors/readers for more resources
Myc proteins (c-myc, Mycn and Mycl) target proliferative and apoptotic pathways vital for progression in cancer. Amplification of the MYCN gene has emerged as one of the clearest indicators of aggressive and chemotherapy-refractory disease in children with neuroblastoma, the most common extracranial solid tumor of childhood. Phosphorylation and ubiquitin-mediated modulation of Myc protein influence stability and represent potential targets for therapeutic intervention. Phosphorylation of Myc proteins is controlled in-part by the receptor tyrosine kinase/phosphatidylinositol 3-kinase/Akt/mTOR signaling, with additional contributions from Aurora A kinase. Myc proteins regulate apoptosis in part through interactions with the p53/Mdm2/Arf signaling pathway. Mutation in p53 is commonly observed in patients with relapsed neuroblastoma, contributing to both biology and therapeutic resistance. This review examines Myc function and regulation in neuroblastoma, and discusses emerging therapies that target Mycn. Oncogene (2010) 29, 1249-1259; doi:10.1038/onc.2009.512; published online 25 January 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available